Human variability underlies differences in the degrees and ways in which people respond to environmental chemicals, and addressing these differences is a key consideration in human health risk assessments for chemicals \[[@r34]; [@r40]; National Research Council (NRC) 2009\]. A large array of possible health outcomes is of concern for such assessments, and many sources of variation can influence the severity and frequency of the adverse effects at different exposure levels. These sources may be intrinsic (e.g., heritable traits, life stage, aging), or extrinsic, exogenous, and acquired (e.g., background health conditions, co-occurring chemical exposures, food and nutrition status, psychosocial stressors). Interactions between inherent and extrinsic factors create the large range of biological variation exhibited in response to a chemical exposure (NRC 2009). Given that biological variability in susceptibility is context-dependent, so too is the extent to which it needs to be described and quantified to inform any particular environmental decision. The salience of variability information for specific choices is affected by the range of available risk management options; the regulatory authority; the available time, resources, and expertise to collect data and conduct analyses; and stakeholder concerns.

Over the past decade, efforts to systematically "map" human variability have expanded dramatically, focusing mainly on genetic variation ([@r87]). In addition to genetic differences, omics studies have examined the impact of epigenetic, transcriptomic, proteomic, and metabolomic variation on disease susceptibility, prognosis, or options for pharmacotherapy ([@r13]; [@r22]; [@r48]; [@r63]; [@r86]). Tailored chemotherapy treatment based on patient ([@r76]) or tumor ([@r59]) genetics is an example of a significant success in applying such discoveries; however, for many diseases, the substantial nongenetic variation in disease or treatment outcomes has limited their utility. Thus, the characterization of the broad set of environmental factors, including those related to chemical exposures, that may contribute to disease is directly relevant to both personalized medicine and environmental health protection ([@r56]).

In this review, we explore how next-generation ("NexGen") human health risk assessments of chemicals might take advantage of novel data to better characterize and quantify variability in susceptibility, by using and expanding upon current analytical methods. We begin by describing biological variability through the conceptual framework of the source-to-outcome continuum. Next, the utility of that framework is illustrated in a review of current approaches to describing variability in susceptibility in human health risk assessments. Then, emerging data streams that may be informative in characterizing human variability in susceptibility are described. Finally, we consider the opportunities, challenges and methods for using emerging data to help assess interindividual variability in responses to environmental chemicals across different decision contexts.

Susceptibility as a Function of the Source-to-Outcome Continuum and Biological Variability
==========================================================================================

The "source-to-outcome continuum" \[U.S. Environmental Protection Agency (EPA) 2007; NRC 2007\] is a conceptual framework for human health risk assessment of environmental chemicals in which changes in the sources of chemicals in the environment are further propagated within the individual through a series of biological and physiological steps that may ultimately manifest as an adverse health outcome ([Figure 1](#f1){ref-type="fig"}):

![Framework illustrating how susceptibility arises from variability. Multiple types of biological variability intersect with the source-to-outcome continuum, either by modifying how changes to source/media concentrations propagate through to health outcomes or by modifying the baseline conditions along the continuum. The aggregate result of all these modifications is variability in how a risk management decision impacts individual health outcomes. The parameters and initial conditions along the source-to-outcome continuum serve as indicators of differential susceptibility, some of which are more or less influential to the overall outcome (see Figure 2).](ehp.1205687.g001){#f1}

*Source/media concentrations* are measures of the chemical, which may change under specific risk management options being considered. A given risk management decision may differentially affect media concentrations depending on local conditions.

*External doses* are measures of exposure (e.g., concentration in air × breathing rate per body weight) to or intake (e.g., amount ingested per body weight) of environmental chemicals, and are related to source/media concentrations by exposure pathways. Sources of variability that may confer susceptibility include differences in behaviors, such as breathing rates, water consumption, and dietary habits (e.g., the amount of fish consumed), and, in an occupational context, use of personal protective equipment.

*Internal doses* are the amounts/concentrations of environmental chemicals or their metabolites at the target site(s) of interaction with biological molecules, and are related to external doses by pharmacokinetic (PK) processes. Susceptibility may arise from differences in compartment sizes and composition (e.g., fat concentration in plasma, which rises during pregnancy) ([@r83]), as well as differences in the rates of uptake (e.g., fraction absorbed from diet or air), metabolism, elimination, and transport to sites of action (e.g., the blood--brain barrier). Such differences may be due, for example, to genetics (e.g., via polymorphisms in metabolic enzymes, uptake and efflux transporters), other chemical exposures (via metabolic enzyme induction and inhibition), and preexisting health conditions and life stage (e.g., via metabolism and mobilization from tissue storage).

*Biological responses* are measures of biological state (e.g., the concentration of glutathione) altered by interactions with environmental chemicals or their metabolites, and are related to internal doses by pharmacodynamic (PD) processes. Variation leading to differential susceptibility can stem from differences in transport systems, receptors and/or proteins in other toxicity pathways, as well as repair capacity (of, for example, DNA), which in turn are affected by intrinsic and extrinsic factors such as genetics and life stage.

*Physiological/health status* reflects the overall state, structure, or function of the organism and is related to biological responses through systems dynamics, the underlying physiological status of the host to which the chemical-specific perturbation is added. Examples include maintenance and adaptation processes (associated with preexisting health conditions, sex hormone levels, for example), and the accumulation of damage events from past exposures (e.g., loss of alveolar septa from past cigarette smoke exposure). Variation in these can confer susceptibility by altering the likelihood of progression from normal function to mild perturbations, early disease, and late disease. Systems dynamics describes the propagation of biological perturbations regardless of whether they are due to chemical exposure, thus distinguishing it from pharmacodynamics, which describes how chemical exposure causes biological perturbations.

[Figure 2](#f2){ref-type="fig"} illustrates the distinct effects of different sources of variability on external dose, internal dose, or biological response. The first category of biological variability is indicated by differences in the parameters governing the relationship of one measureable quantity to the next (e.g., external to internal dose, and internal dose to biological response) ([Figure 2A,B](#f2){ref-type="fig"}). In addition, there may be biological variability in the initial conditions for each measureable quantity, as well as the contribution from the source of environmental chemical exposure under consideration for risk management ([Figure 2C,D](#f2){ref-type="fig"}). For example, increases in background exposure to the same or a different chemical(s) may result in saturation of metabolic activation and/or clearance processes, or temporary depletion of cofactors involved in detoxification, such as glutathione, resulting in either attenuation or amplification of the effect of additional increments of chemical exposure on internal dose ([Figure 2C](#f2){ref-type="fig"}). Nonetheless, a biological response with a low background level may be much less altered by additional exposure than one with a high background because of to the cooperativity associated with a relatively higher baseline internal dose ([Figure 2D](#f2){ref-type="fig"}).

![Effects of variability in PK (*A*), PD (*B*), background/coexposures (*C*), and endogenous concentrations (*D*). In (*A*) and (*B*), individuals differ in PK or PD parameters. In (*C*) and (*D*), individuals have different initial baseline conditions (e.g., exposure to sources outside of the risk management decision context; endogenously produced compounds).](ehp.1205687.g002){#f2}

Current Approaches to Addressing Variable Susceptibility
========================================================

Variability for assumed threshold-like dose--response relationships is currently addressed by applying an "uncertainty" or "adjustment" factor (U.S. EPA 2011). The factor to account for interindividual variability in human population has typically been 1, 3, or 10. In some cases, the factor is further divided to separately account for variation in PK and PD (U.S. EPA 2011; [@r49]). In this context, PD has included both PD and systems dynamics processes described above and in [Figure 1](#f1){ref-type="fig"}. Data permitting, the PK component can be addressed through physiologically based pharmacokinetic (PBPK) modeling, in which case a factor addressing only PD is applied (U.S. EPA 2011). Occasionally, exposure--effect observations are available for particularly susceptible human populations, such as with ozone and persons with asthma (U.S. EPA 2006), or those sensitive to chronic beryllium disease (U.S. EPA 1998), which allows for a data-driven estimation of the likely impact of interindividual variability on human health risk assessments.

For presumed nonthreshold cancer end points, interindividual variability is not currently addressed when risk is estimated from animal studies, with the exception that for mutagenic compounds exposures occurring early in life are weighted more heavily (by a factor of 10 between birth and 2 years of age, and a factor of 3 between 2 and 16 years of age). Cancer risk for susceptible populations, such as smokers who have been exposed to radon, may be calculated in addition to that for a general population (U.S. EPA 2003). Alternatively, adjustments may be made to address susceptible subgroups, such as the sex-specific effects of 1,3-butadiene (U.S. EPA 2002). There have been calls to formally account for variability in cancer dose response (NRC 2009).

Over the past 30 years, several strategies to characterize (predominantly PK) variability combining mathematical models and statistical distributions have developed in parallel. The first strategy, mostly used for data-rich pharmaceuticals, couples empirical PK models and multilevel (random effect) statistical models to extract *a posteriori* estimates of variability from clinical data on patients or volunteers. This "population PK" approach ([@r2]) seeks to measure variability and to discover its determinants. The second, the "predictive PK," approach takes advantage of the predictive capacity of mechanistic models and assigns *a priori* distributions to their parameters (e.g., blood flows, organ volumes). The parameters having biological meaning can be observed through independent experiments, clinical measurements, or surveillance. [Table 1](#t1){ref-type="table"} lists some examples of data sources for developing *a priori* parameter distributions. Monte Carlo simulations are used to propagate the distributions from model parameters to model predictions ([@r77]; [@r89]). A third approach, the "Bayesian PBPK" approach, offers a synthesis of the other two, applying mechanism- or chemical-specific parameter variability data from a variety of independent sources while using population observations of relevant biomarkers of internal exposure and effect to further inform parameter variability ([@r1]; [@r3]; [@r35]). Parameter covariance can be modeled by multivariate prior distributions ([@r12]) or joint posterior distributions obtained by Bayesian multilevel modeling ([@r9]; [@r98]). A Bayesian PBPK model-based analysis of the population toxicokinetics of trichloroethylene (TCE) and its metabolites in mice, rats, and humans provides a practical example of how a systematic method of simultaneously estimating model parameters and characterizing their uncertainty and variability can be applied to a large database of studies on a chemical with complex toxicokinetics ([@r15]).

###### 

Examples of data sources for modeling PK and PD variability.

  Example                                                                                                                                                        References
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  Variability in human phase I and phase II metabolism and renal excretion, including in different age groups--neonates, children, and the elderly               Dorne 2010; Ginsberg et al. 2002, 2004; Hattis et al. 2003
  Compilations of genetic polymorphisms of specific metabolic enzyme activities:                                                                                 
  Paraoxonase                                                                                                                                                    Ginsberg et al. 2009a
  N-Acetyltransferase 1 and 2                                                                                                                                    Bois et al. 1995; Walker et al. 2009
  Glutathione transferases                                                                                                                                       Ginsberg et al. 2009b
  CYP2D6 (cytochrome P450 2D6)                                                                                                                                   Neafsey et al. 2009b
  CYP2E1 (cytochrome P450 2E1)                                                                                                                                   Neafsey et al. 2009a
  ALDH2 (acetaldehyde dehydrogenase 2)                                                                                                                           Ginsberg et al. 2009c
  Human biomonitoring observations of interindividual differences in biomarkers of exposure (e.g., chemical-protein adducts) or in levels of parent/metabolite   Bois et al. 1996
  Variability in physiological parameters for older adults: bodymass, surface area, body mass index, health status                                               Thompson et al. 2009
  Indicators of PD variability                                                                                                                                   
  Human DNA repair enzyme XRCC1                                                                                                                                  Ginsberg et al. 2011
  Human host defense enzymes                                                                                                                                     Ginsberg et al. 2010
  Lung function response to particulate matter                                                                                                                   Hattis et al. 2001
  Susceptibility to infectious organisms                                                                                                                         Hattis 1997

PBPK models have been often used to assess variability on the basis of prior parameter distributions obtained from *in vitro* experiments or the physiological literature ([@r7]; [@r50]) and can include genetic information regarding variability. For example, PBPK models can inform the implications of polymorphisms in metabolism genes ([@r52]). The effects of such polymorphisms on PK of environmental toxicants and drugs have been the subject of many empirical studies (reviewed by [@r30], [@r25]). These polymorphisms are of particular concern for xenobiotics whose metabolic fate or mechanism(s) of action is controlled by a particular enzyme ([@r25]), and in such cases genetic variability can profoundly influence enzyme function with implications for internal dose ([Figure 1](#f1){ref-type="fig"}). However, because enzymatic pathways with overlapping or redundant function and other pharmacokinetic factors (e.g., blood flow limitation) can also influence metabolic fate ([@r55]), PBPK models are needed to evaluate the implication of genetic polymorphisms in metabolizing enzymes in human health risk assessment ([@r25]).

The situation is somewhat different for PD and systems toxicology models. The biologically based dose--response models describe apical or intermediate end point responses as a function of PK-defined internal doses ([@r17]). However, models designed purely from our understanding of the disease process, such as the role of cytotoxicity and regenerative proliferation in carcinogenesis ([@r62]), or the effect of dietary iodide and thyroid hormones on the hypothalamic--pituitary--thyroid axis ([@r66]), require further development to reliably predict an adverse outcome from tissue exposure (the last two arrows in [Figure 1](#f1){ref-type="fig"}), or its variability. Understanding a disease process at the pathway level (i.e., PD and systems dynamics components of the source-to-outcome continuum) is in itself not sufficient to define reliable and informative mechanistic models because of great model sensitivity to uncertain inputs. Most such models are based on equations derived from the classical receptor theory ([@r18]) and focus on PD rather than system dynamics elements of the disease process and do not attempt to model the full process from tissue exposure to disease outcome.

Emerging Data Streams on Biological Variability
===============================================

Experimental population-based paradigms to address intrinsic variability in response to exposure comprise multiple levels of biological organization, from molecules to whole bodies. Published examples, reviewed by [@r84], include animal models and large-scale *in vitro* screening platforms to study population-based genetic determinants. Those studies have also aided in the identification of genetic susceptibility factors that underlie toxicity phenotypes. Complementary to these are genome-wide ([@r47]) and exposure-wide ([@r74]) association studies for assessing human population variability.

*Experimental* in vitro *data on genetic variability.* Human cell lines obtained from genetically diverse subjects and multiple populations ([@r21]) hold the promise of providing data for assessing genetic determinants of different components of toxic response. Many recent studies have used human lymphoblastoid cell lines, representative of the genetic diversity in populations of European, African, Asian, and North and South American ancestry, to quantify interindividual and interpopulation variability in response to drugs ([@r101]). Dozens of studies published in the past 5 years have profiled the cytotoxicity of single to as many as 30 drugs (mostly chemotherapeutics) in hundreds of cell lines. Diverse applications for such a population-based cell model has been suggested. Drug class--specific signatures of cytotoxicity, which could indicate possible shared mechanisms, have been identified and replicated in both cell lines from different populations and for additional compounds ([@r100]). Furthermore, such studies may potentially inform the prioritization of chemotherapeutic drugs with a sizable genetic response component for future investigation ([@r75]) and assist in identifying germline predictors of cancer treatment outcomes ([@r45]).

The utility of such *in vitro* models to toxicology, especially for exploring the extent and nature of genetic components of interindividual variability in PD and systems dynamics, was recently demonstrated ([@r60]; [@r73]). Quantitative high-throughput screening (qHTS) produced robust and reproducible data on intracellular levels of adenosine triphosphate and caspase-3/7 activity (i.e., biological response) indicative of general cytotoxicity and activation of apoptosis (i.e., physiological status), with utility for variability assessment as follows. First, standardized and high-quality concentration--response profiling, with reproducibility confirmed by comparison with previous experiments, enables prioritization of chemicals based on interindividual variability in cytotoxicity. Second, genome-wide association analysis of cytotoxicity phenotypes allows exploration of the potential genetic determinants of that variability. Finally, the highly significant associations between basal gene expression variability and chemical-induced toxicity suggest plausible mode-of-action hypotheses for follow-up analyses.

Several extensions of these studies can be envisioned to advance the identification of determinants of genetic susceptibility and variability in toxic response. Opportunities include the testing of additional, and more diverse, chemicals (including major metabolites) and concentrations (to account for lower metabolic capacity of these cells). Other specific end points could also be assessed. Further, these studies could be expanded to include larger panels of lymphoblasts and other cell types from genetically and geographically diverse populations. Development of related assay systems to monitor differences in susceptibility to perturbation of communication between cells (e.g., neurotransmission or differentiation signals) could address other aspects of variability not present in cultures comprising only one kind of cell. The development and use of these and other types of *in vitro* assays would be further informed by quantitative comparisons of the PD interindividual variability measured *in vitro* with observable human pharmacodynamics variability *in vivo*. Candidate chemicals for this comparison would be selected environmental toxicants (such as ozone) and pharmaceuticals that have been tested for responses in appreciable numbers of human subjects at different known exposure levels. The extent of interindividual variability in response that was observed for different chemicals in *in vitro* assays could also be compared with previously collected sets of *in vivo* human PD variability data ([@r40]).

*Experimental* in vivo *data.* Several proof-of-concept studies that utilized a "mouse model of the human population" have demonstrated the potential for translation to clinical applications and for addressing both PK and PD components of variability ([@r33], [@r32]; [@r38]; [@r57]; [@r78]). For example, the extent and nature of TCE metabolism is an important consideration in relating adverse health effects in rodents to humans. [@r10] measured variability in PK for TCE using a panel of inbred mouse strains, revealing marked differences among individual mice (e.g., a greater than 4-fold difference in peak serum concentrations of TCE metabolites). These experimental data on intraspecies differences in TCE metabolism may be used to calibrate the variability in outputs of PBPK models, and thus inform quantitative assessment of variability in TCE metabolism across species.

With regard to PD variability, genetically diverse mouse strains can be used to understand and predict adverse toxicity in heterogeneous human populations. For example, [@r37] evaluated the role of genetic factors in susceptibility to acetaminophen-induced liver injury in a panel of inbred mouse strains and two cohorts of human volunteers. The authors identified genes associated with differential susceptibility to toxicity in a preclinical phase. This finding has the potential to focus further toxicogenetics research, overcome the challenges of studies in small human cohorts, and shorten the validation period. The data acquired with this model may be used in analyses of individual risk to toxicants. Furthermore, when combined with omics data collected on an exposed population of individual strains, it may be possible to explore underlying genotype-dependent and -independent toxicity pathways involved in PD response ([@r10]; [@r37]).

Experiments such as these afford the opportunity to quantitatively understand the interplay between genetics, PD, and systems dynamics. In addition, genetically defined mouse models may be used to supplement the limited data from human studies to not only discover the genetic determinants of susceptibility and understand the molecular underpinnings of toxicity ([@r37]; [@r58]) but also to develop descriptions of variability for use in dose--response and mechanistic evaluation components of human health risk assessments.

Such rodent systems can also be used to assess the role of epigenetics, as well as its potential interplay with the genetic background, in susceptibility. For example, [@r58] demonstrated that interstrain differences in susceptibility to 1,3-butadiene--induced genotoxicity may be due to strain-specific epigenetic events that are also part of a PD response.

Practical use of this type of experimental information is possible mainly when the mechanistic pathways to human adverse responses are better established. More general application will also depend on the development of suites of rodent models that more fully represent human diversity in both genetics and other factors, such as age ([@r36]). Such studies can, in turn, provide important insights concerning the identity and extent of sources of variability that may arise in the source-to-outcome continuum for a given chemical class, physiologic state, or adverse response.

*Human clinical and observational data.* Genome-wide association studies (GWAS) with disease severity as the phenotypic trait are used to associate genetic loci with risk for complex diseases ([@r81]). Even though GWAS approaches have uncovered numerous genomic loci that may affect the risk of human disease ([@r63]), the identified variants explain only a small proportion of the heritability of most complex diseases ([@r64]). Some have suggested that unexplained heritability could be partly due to gene × environment interactions, or complex pathways involving multiple genes and exposures ([@r87]).

The GWAS concept is now being applied to identify additional genotype-dependent metabolic phenotypes and to gain insight into nongenetic factors that contribute to the effects of xenobiotics on system dynamics. In animal studies, metabolic phenotype-related quantitative trait loci were shown to be useful in understanding genome × phenotype relationships and how extended genome (microbiome) perturbations may affect disease processes through transgenomic effects ([@r20]). In a series of human studies ([@r23]; [@r48]; [@r90]), serum collected from two large European cohorts (2,820 individuals in total) was analyzed with nontargeted metabolomics, focusing on endogenous metabolites and covering 60 biochemical pathways. Ratios of metabolites to parent chemical concentrations served as surrogates for enzymatic rate constants. Thirty-seven genes were associated with blood metabolite concentrations and, in some cases, explained a substantial fraction of the variance. Endogenous and xenobiotic metabolites (mostly of drugs) were studied.

Clinical ([@r11]; [@r43]) and epidemiological ([@r51]; [@r104]) studies of acute and chronic effects of ambient air exposures have long had important roles in quantifying human variability in the risks of exposures to widespread toxicants such as ozone and airborne particulates. The addition of GWAS to these established tools has the potential to widen the capability for quantification of effects on susceptibility of many individual genotypic variants that individually have relatively modest effects ([@r44]). Establishing the roles of individual pathways in affecting susceptibility via genetic analysis, in turn, has the potential to advance the assessment of effects of other exposures during life that also affect the same pathways. Elucidating these determinants for prominent toxicants, however, requires a very considerable research effort. Nonetheless, this research paradigm provides opportunities to explore variability in adverse responses that is due to physiological states for which *in vitro* and experimental animal models are lacking.

Variability in human response to an agent stems in part from differences in the underlying exposures that contribute to a given disease response prevalence within the population. A person's internal "chemical environment" may be as important for possible disease associations as exposures to the variety of chemicals in the external environment. Under this "exposome" concept ([@r102]), exposures include environmental agents and internally generated toxicants produced by the gut flora, inflammation, oxidative stress, lipid peroxidation, infections, and other natural biological processes ([@r79]).

Advances in *in Silico* Methods to Address Human Variability
============================================================

Modeling of variability is expected to be needed for both data-rich and -sparse chemicals. Recent advances in software, publicly available data and ongoing computational activities in biomedical research should facilitate the development and use of the results of this type of modeling.

*Modeling the PK dimension of human variability.* Commercial software products \[e.g., by Simcyp (<http://www.simcyp.com>), Bayer Technology (<http://www.pksim.com>)\] are available to explicitly address variability for pharmaceutical or human health risk assessment applications to, for example, adjust dosing for different target patient populations ([@r50]; [@r103]). Several of these offer generic PBPK models, applicable to "any" substance; however, their substance-specific parameters have to be obtained from *in vitro* experiments (particularly on metabolism) or quantitative structure--property relationships. The variability of subject-specific physiological parameters can be informed by compiled databases (see above) and literature searches ([@r7]; [@r30]), and could include adjustments or protocols to address limitations in data availability. Quantitative structure--property relationship models or *in vitro* data can also be used to derive substance-specific parameters. These models are being applied in an exploratory fashion in *in vitro*--based assessments ([@r54]; [@r82]).

Using a Bayesian multilevel population approach, some of the key parameters of these generic models could be calibrated by integrating human observational data with data from lower levels of biological organization. This presents a computational challenge on a chemical-specific basis, because those models are neither particularly parsimonious nor quickly evaluated. Yet an extensive calibration of a complex generic model for a selected number of data-rich environmental or pharmaceutical chemicals could be used as support to develop generic approaches for PK variability treatment in human health risk assessment. For example, generalizations could be made about the extent to which particular enzymes may contribute to overall human PK. Extensions of the approach of [@r40] can also be developed to construct "bottom up" quantitative descriptions of PK variability that can be applied as defaults across classes of chemicals.

*Modeling the PD dimension of human variability.* Semi-empirical PD models can include observed biomarkers of susceptibility as covariates. Such models are increasingly applied in predictive toxicity and human health risk assessment. Environmental epidemiology also routinely models quantal types of biomarker data in logistic regressions. Harmonizing the tools and models of toxicological risk assessment with those of epidemiological risk assessment, and reconciling their data and results, should facilitate the development of better approaches for background and variability descriptions in NexGen human health risk assessments.

*Integrating PK and PD into a systems biology framework.* The link between toxicity pathway and "normal cell physiology" models of systems biology could also be further developed and used as the basis to explore potential ranges of human variability. The potential of publicly accessible and curated biomodel and database repositories will be increasingly exploited as familiarity increases in the risk assessment and risk management communities. Importantly, systems biology models can describe background biological processes and the impact of their perturbation and provide a framework for exploring human variability and identifying susceptible populations for targeted assessment and management efforts. Although they come at the price of tremendous complexity, their development can leverage the considerable ongoing effort by the biomedical and pharmaceutical research community to support applications other than toxicant risk evaluation. Further, because of these large-scale efforts, the necessity of sharing and standardization is well understood in the United States. The systems biology markup language ([@r46]), for example, is a high-level language developed explicitly to provide a common intermediate format for representing and exchanging systems biology models. Predictive toxicology will benefit from these developments.

The frontier for both PK and PD is in the integration of the rapidly growing information about metabolic networks, receptors, and their regulation with toxicity pathways. The models so far most amenable to quantitative predictions are differential equation models. PBPK models will likely be merged with systems biology and virtual human models. The boundary between PK and PD actually tends to blur as metabolism becomes more and more integrated into detailed models of toxicity pathways when, for example, modeling enzymatic induction by xenobiotics ([@r4]; [@r61]). The variability of the different components of those models will be directly informed by time series of genomic, proteomic, metabolomic data on the chemical species considered. This may provide a framework for assessing the variability in susceptibility to chemically induced effects as influenced by possible metabolic interactions as well as preexisting disease. In time this may facilitate computing the impact of, for example, single nucleotide polymorphisms on the reaction rates of enzymes and receptors and translating these calculations to estimates of human variability ([@r67]). Ongoing work on simulations of enzymatic reactions or receptor binding at the atomic level (e.g., the potassium channel pore) shows the way forward for predicting fundamental reaction rates by physical chemistry approaches. Prediction of the quantitative impact of sequence or amino-acid variation on the function of the reactive species involved in systems biology models is coming within reach ([@r31]; [@r85]).

Biologically based PD models, such as the systems biology models of response networks ([@r88]), models of toxicity pathway perturbations, and biologically based dose--response models proposed to link biochemical responses to apical effects, clearly hold promise ([@r18]; [@r53]; [@r70]) but face challenges similar to those that hampered the use of biologically based cancer models ([@r5]; [@r14]). To explore the extent of human variability in response to toxicant and stressor exposures, the various steps in the relevant causal path need to be modeled quantitatively and on a population basis. A problem is that the quantitative linking of omics biomarkers to risk is missing. For many markers (e.g., of apoptosis, cell division), the linkage to risk is highly uncertain ([@r105]), so the ranges of possible variability may be very large. Further, the ability to reinforce information by linking with the impact of injury on multiple targets is also limited because such links are generally not well understood.

Implications for NexGen Human Health Risk Assessments
=====================================================

Multiple "tiers" of human health risk assessment needs, requiring different levels of precision, can be envisioned. These include screening-level analyses of multiple chemicals to inform the prioritization of management and enforcement actions across communities, ensuring protection across the population to widespread exposure to legacy contaminants, or identifying subpopulations for which differing risk management options might be applied.

In the lowest (simplest) tier of assessments, evaluations are expected to primarily rely on the results of high- and medium-throughput *in vitro* screening tests in mostly human cell lines, as well as complementary *in silico* predictive methods. The Tox21 collaboration ([@r16]) is leading the field in exploring how a broad spectrum of *in vitro* assays, many in qHTS format, can be used to screen thousands of environmental chemicals for their potential to disturb biological pathways that may result in human disease ([@r106]). Such data on toxicologically relevant *in vitro* end points can be used as toxicity-based triggers to assist in decision making ([@r80]), as predictive surrogates for *in vivo* toxicity ([@r65]; [@r108]), to generate testable hypotheses on the mechanisms of toxicity ([@r107]), and to develop screening assays based on pathway perturbations. The extent of interindividual variability in toxic response to be estimated from these types of assays can be informed by empirical data and PK/PD models that address multiple factors in the source-to-outcome continuum as described in [Figure 1](#f1){ref-type="fig"}. The genomic component of variability may be partially informed by test data from genetically diverse but well-defined human cell lines, such as from the HapMap (<http://hapmap.ncbi.nlm.nih.gov/>) and 1000 Genomes (<http://www.1000genomes.org/>) projects. For example, emerging data based on standardized and high-quality concentration--response profiling can help inform characterizations of the extent of interindividual variability in cytotoxicity. When chemical-specific estimates are lacking, the range of interindividual variability for structurally related compounds may be informative, in a read-across approach. Quantitative data characterizing the range in response (e.g., size and variance) may be integrated with probabilistic default distributions addressing the remaining key sources of interindividual variability. Quantitative estimates of PK variability would be also incorporated. In addition, factors such as life stage and background exposures may be particularly important considerations for approaches accounting for baseline differences in the spectrum of the "chemical environment" ([@r79]), in interpreting results from the omics assays, and in evaluating the potential contributions of nongenetic variability factors.

At these lower tiers, a probability distribution may best acknowledge the many uncertainties involved in making inferences with limited data. Systematic analyses of chemical sets will be needed to refine distributions for the chemical-specific and general case. For instance, external comparisons of *in vitro* measures based on genetic variability in pharmacodynamics to *in vivo* observations may inform the choice of distribution used for a particular chemical or chemical category. Standard categories, comprising different size and variance distributions for multiple variability factors that can then be applied to other chemicals, may emerge from these analyses. The ranking and grouping of chemicals for the application of these distributions may be based on structural class, the relative extent of observed variability, a common determinant of variability (e.g., as identified in GWAS analysis of cytotoxicity phenotypes), or other factors (e.g., likelihood of coexposures or confounders). Compounds demonstrated or predicted to have highly variable toxic responses may also be given a higher priority for further study, in combination with chemical and other expected modifiers of susceptibility.

At higher tiers of NexGen human health risk assessments, animal and in some cases human data are available for evaluating dose--response relationships, major pathways for some of the critical toxicities for risk assessment can be reasonably well understood, and some *in vivo* human data relevant to those pathways may be available. For some chemicals, sensitive populations may have been identified and studied using omics technologies. In the case of ozone, for example, gene expression data and genomic markers may be collected on individuals of high and average sensitivity. Toxicity pathways exhibited in cultured airway epithelial cells exposed to ozone may also be compared with those in humans exposed *in vivo* to ozone. Such data will aid a better characterization of the dose--time--response severity relationships at low doses. In other cases, where individuals are studied epidemiologically, the current bioinformatics analyses lack power and require pooling of subjects to detect trends, losing variability estimation in the process. In such cases, there will be a need to couple default descriptions of PD variability with PBPK modeling to obtain an overall prediction of variability. In the future, new hypothesis-based molecular clinical and epidemiological approaches that integrate emerging biological knowledge of pathways with observations of physiological disease status, markers of early biological response, and genetics are likely to provide the way forward with population-based descriptions of variability.

Conclusions
===========

Emerging data streams can inform multiple aspects of biological variability, be used in different modeling approaches addressing PK and/or PD variability, and have application across different chemical screening and evaluation schemes. Successful examples of addressing PK variability include the development and application of a Bayesian PBPK model--based analysis systematically estimating model parameters and characterizing their uncertainty and variability for TCE, a chemical with complex toxicokinetics ([@r15]). Additionally, data from animal models and large-scale *in vitro* screening platforms that have incorporated population-based genetic determinants (reviewed by [@r84]), have provided insight into the extent of genetic variability in response to a diversity of toxicants, as well as aided in the identification of genetic susceptibility factors that underscore the development of toxic phenotypes. Hypothesis-based molecular clinical and epidemiological approaches to integrating genetics, molecular pathway data, and clinical observations and biomarkers are likely to contribute to population-based descriptions of variability. Complementary to these are genome-wide ([@r47]) and exposure-wide ([@r74]) approaches for assessing human population variability in toxic response. Opportunities exist to employ these emerging data streams in the development of *in silico* predictive models for application in a range of decision-making contexts.

This review was informed by the discussions and presentations at a National Research Council (NRC) workshop titled "Biological Factors that Underlie Individual Susceptibility to Environmental Stressors and Their Implications for Decision-Making" held in April 2012 in Washington, DC.
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